ArticleEuropean journal of medical research2026
Circ-PRKCI attenuates acute lung injury secondary to sepsis by targeting the miR-106b-5p/GAB1 axis.
Article in European journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAcute lung injury (ALI) secondary to sepsis increases the risk of mortality in septic patients. However, the molecular mechanism of alveolar epithelial cell damage in ALI secondary to sepsis remains incompletely understood. Studies demonstrate that circular RNA (circRNA) modulates the progression of ALI secondary to sepsis. This study aims to explore the function and mechanisms of circ-PRKCI in ALI associated with sepsis.
methodsThe in vitro ALI model was constructed by treating MLE-12 cells with LPS. The expression of circ-PRKCI, miR-106b-5p, GRB2-associated binder 1 (GAB1), and inflammatory cytokines was measured via RT-qPCR. The expression of apoptosis-related proteins and GAB1 protein was analyzed via Western blot. The subcellular localization of circ-PRKCI was determined using immunofluorescence. Cell viability was measured by the CCK-8 assay, and apoptosis was evaluated using flow cytometry. ELISA was employed to measure pro-inflammatory cytokine concentrations in cells and lung tissue samples. The content of oxidative stress markers was measured utilizing corresponding assay kits. The binding relationship between miR-106b-5p and circ-PRKCI or GAB1 was validated through dual-luciferase reporter assays and RNA RIP experiments. The in vivo ALI model was constructed via cecal ligation and puncture (CLP) surgery. HE staining and the W/D ratio test were performed on mouse lung tissues to evaluate the extent of lung injury.
resultsThe findings revealed that circ-PRKCI attenuated apoptosis, inflammation, and oxidative stress in ALI-induced cells, while also suppressing pulmonary inflammation, edema, and apoptotic responses in the murine ALI model. However, miR-106b-5p was capable of reversing the function of circ-PRKCI. Mechanistically, circ-PRKCI modulated the expression of GAB1 by competitively binding to miR-106b-5p.
conclusionOur findings indicated that circ-PRKCI attenuates ALI secondary to sepsis by targeting the miR-106b-5p/GAB1 axis, suggesting that circ-PRKCI holds potential as a therapeutic target for ALI secondary to sepsis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.